|
Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1. |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Abbvie; Amgen; Celgene; Genentech/Roche; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Pfizer; Sanofi; Takeda |
Research Funding - Celgene (Inst); Janssen (Inst) |
| |
|
Honoraria - Celgene; Janssen; Pfizer; Takeda |
Consulting or Advisory Role - Celgene; Janssen; Pfizer; Takeda |
Research Funding - Celgene; Janssen; Takeda |
| |
|
Honoraria - Medscape; Research to Practice |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Merck; Takeda |
Research Funding - 2seventy bio |
| |
|
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Karyopharm Therapeutics; Sanofi; Seagen; Takeda |
| |
Bhagirathbhai R. Dholaria |
Stock and Other Ownership Interests - Iovance Biotherapeutics; Syndax |
Honoraria - Adaptive Biotechnologies; Curio Science; MJH Healthcare Holdings, LLC; Wiley |
Consulting or Advisory Role - arivan research; Beam Therapeutics; Gamida Cell; Jazz Pharmaceuticals; Pluristem Therapeutics |
Research Funding - Angiocrine Bioscience (Inst); Janssen Oncology (Inst); MEI Pharma (Inst); Orca Bio (Inst); Pfizer (Inst); poseida therapeutics (Inst); Takeda (Inst); WUGEN, Inc. (Inst) |
| |
|
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline |
Consulting or Advisory Role - Bristol-Myers Squibb; Pfizer; Seagen |
Research Funding - ADC Therapeutics; Partner Therapeutics |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Karyopharm Therapeutics; Pfizer; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline |
Research Funding - Amgen; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Janssen; Pfizer |
| |
|
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Gracell; Janssen; Karyopharm Therapeutics; Sanofi |
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Gracell; Janssen; Karyopharm Therapeutics; Sanofi |
| |
|
|
Consulting or Advisory Role - Abbvie/Genentech; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Oncopeptides; Sanofi |
Speakers' Bureau - BMS; GlaxoSmithKline; Karyopharm Therapeutics; Oncopeptides; Sanofi |
Research Funding - Abbvie (Inst); BMS (Inst); Karyopharm Therapeutics (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - GlaxoSmithKline; Karyopharm Therapeutics; Sanofi |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - BMSi; focus therapeutics; Gilead Sciences; Janssen; Janssen; Pfizer |
Patents, Royalties, Other Intellectual Property - Patent but with no associated royalties or profit |
| |
|
Honoraria - ITeos Therapeutics; Janssen; Legend Biotech; Pfizer; Sanofi; Trillium Therapeutics |
Consulting or Advisory Role - Pfizer; Trillium Therapeutics |
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst); Trillium Therapeutics (Inst) |
Patents, Royalties, Other Intellectual Property - Serametrix, Inc |